Interview with Dr James Garner, CEO of Kazia Therapeutics
-
Non Regulatory August 15, 2022Vivesto notes the launch of Apealea® in Germany by Inceptua
-
Regulatory July 21, 2022Vivesto appoints Christer Nordstedt as acting CEO
-
Regulatory July 5, 2022Vivesto winds down its activities in Russia
Vivesto published its Q1 2022 report on May 25, 2022, at 08.00 am CET.
Oasmia acquires global development and commercialization rights for Cantrixil, a clinical stage, ovarian cancer program
For #investors and #media:
Today Inceptua launched Apealea® in Germany. This is great news for patients but also for Vivesto’s business as we are eligible for royalties on any sales.
#oncology #biotech
Vivesto notes the launch of Apealea® in Germany by Inceptua - Vivesto
Solna, Sweden, 15 August 2022 – Vivesto AB, an oncology-focused specialty pharmaceutical company, is pleased to note...
www.vivesto.com
This #MensHealthWeek have a look at this campaign by @menshealthforum all about how to carry out a MAN-MOT. Your car gets one regularly so why not all men? This article shows how to do your own and help early diagnosis of Prostate cancer.
Read more here:
DIY Man MOT
Your car gets one regularly but what about you? No, not a parking ticket, an MOT. Giving your body a once-over...
bit.ly